Business Context and Reporting Period
Company: BioLife Solutions, Inc. (BLFS)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: BioLife develops and markets bioproduction products and services for the cell and gene therapy (CGT) industry, including biopreservation media, automated thawing devices, and cloud-connected shipping containers. The company operates as a single reportable segment.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | 6M 2025 | 6M 2024 |
|---|---|---|---|---|
| Total Revenue | $25,421 | $19,715 | $49,362 | $38,148 |
| Net Loss (Continuing Ops) | $(15,838) | $(5,560) | $(16,286) | $(8,759) |
| Operating Loss | $(16,643) | $(1,306) | $(17,860) | $(4,601) |
| Net Cash from Operating Activities | N/A | N/A | $9,095 | $1,984 |
| Cash & Equivalents (End of Period) | $31,902 | $22,045 | $31,902 | $22,045 |
| Total Liquid Assets (Cash + AFS) | $100,200 | $31,243 | $100,200 | $35,873 |
| Total Debt (Current + Long-term) | $10,051 | $15,940 | $10,051 | $15,940 |
Note: Q2 2024 Net Loss includes discontinued operations of $(15,159)k. Q2 2025 Net Loss is from continuing operations only as discontinued operations were divested in 2024.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 29% year-over-year for both the quarter and six months ended June 30, 2025. Cell processing product revenue grew 28% (Q2) and 30% (6M), driven by increased customer demand and market recovery from prior year safety stock reductions.
- Acquisition Impact (PanTHERA): The company acquired PanTHERA CryoSolutions Inc. on April 4, 2025. This resulted in a one-time IPR&D expense of $15.5 million recorded in Q2 2025, significantly impacting the operating loss. The acquisition was accounted for as an asset acquisition.
- Discontinued Operations: The company divested Global Cooling, SciSafe, and Custom Biogenic Systems (CBS) in 2024. These are reported as discontinued operations. Q2 2024 results included a loss from discontinued operations of $15.2 million, primarily due to the Global Cooling divestiture loss.
- Operating Expenses: Total operating expenses increased 100% in Q2 2025 compared to Q2 2024, largely due to the $15.5 million IPR&D charge. Excluding this charge, G&A expenses increased 22% due to higher personnel costs and stock-based compensation.
- Investing Activities: Net cash used in investing activities increased to $66.7 million for the six months ended June 30, 2025, primarily driven by $64.3 million in purchases of available-for-sale securities and $10.2 million in cash paid for the PanTHERA acquisition.
Guidance, Outlook, and Risks
- Liquidity: Management believes current cash, cash equivalents, and available-for-sale securities ($100.2 million as of June 30, 2025) are sufficient to meet liquidity needs for at least the next 12 months.
- Debt Obligations: The company has a Term Loan with a maturity date of June 1, 2026. As of June 30, 2025, the outstanding balance was $10.0 million (current portion). The loan bears interest at the WSJ prime rate plus 0.5%.
- Stock-Based Compensation: Total stock-based compensation expense was $10.0 million for the six months ended June 30, 2025, up from $8.1 million in the prior year period. Unrecognized compensation costs remain significant ($23.6 million for service-based awards).
- Risks:
- Valuation Allowance: The company maintains a full valuation allowance of $57.9 million against deferred tax assets due to uncertainty regarding future realizability.
- Legal Contingencies: The company is required to indemnify Global Cooling for a pre-existing product liability lawsuit seeking up to $4.0 million. Management believes insurance will cover the loss, but legal costs may be incurred.
- Concentration Risk: One customer (Customer B) accounted for 14% of revenue in Q2 2025 and 16% in the six-month period. CryoStor products represented 74% of product revenue.
- Subsequent Event: On July 18, 2025, the company purchased $2.0 million of convertible notes in Pluristyx, Inc.
Investor Verification Checklist
- IPR&D Expense: Verify the $15.5 million immediate expensing of the PanTHERA IPR&D asset and its impact on future profitability once the technology achieves commercial viability.
- Debt Maturity: Confirm the repayment schedule for the $10 million Term Loan maturing in June 2026 and the company's ability to refinance or repay without dilution.
- Discontinued Operations: Review the final working capital adjustments for the SciSafe and CBS divestitures to ensure no unexpected liabilities or gains are recorded in future periods.
- Revenue Concentration: Monitor the dependency on Customer B and the CryoStor product line, which together represent a significant portion of revenue.
- Stock-Based Compensation: Assess the trajectory of stock-based compensation expenses, particularly the $23.6 million in unrecognized costs, and its impact on future operating margins.